Dysregulation of GLP-1R signaling contributes to impaired insulin secretion, altered lipid homeostasis, hyperglycemia, and metabolic dysfunction observed in obesity and type 2 diabetes [1]
For eligible adults with clinically significant obesity, MHRA-approved options include semaglutide (Wegovy, assessed in NICE TA875) and tirzepatide (Mounjaro, assessed in NICE TA1026), both available through NHS pathways with appropriate clinical oversight
Yes, we accept most major insurance plans, including Medicare
Evoke and Evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimers disease
GLP-1: Enhances insulin secretion and lowers blood sugar
What the Phase 2 Trial Data Shows According to data reviewed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), understanding clinical trial parameters is essential when setting expectations for any weight management medication
